"Building Bridges to Better Care"

4th Annual Conference (Virtual)

May 21, 2022 9 am - 4:15 pm

Discussions on:

HEAR FROM LEADING NATIONAL EXPERTS IN THEIR FIELDS

Screen Shot 2022-05-05 at 8.40.52 AM

Dr. Eboni Lance, M.D., Ph.D.
Kennedy Krieger Institute, Baltimore, MD
Neurocognition in SCD

Screen Shot 2022-05-05 at 8.41.01 AM

Dr. David Williams, M.D.
Boston Children’s Hospital, Boston, MA
Gene Therapy

Screen Shot 2022-05-05 at 8.41.09 AM

Dr. Matthew Porteus, MD, PhD.
Stanford University, Palo Alto, CA
Gene Therapy

Screen Shot 2022-05-05 at 8.41.16 AM

Dr. Alexis Leonard, M.D.
Children’s National , Washington D.C.
Gene Therapy

Screen Shot 2022-05-05 at 8.41.22 AM

Dr. Rakhi Prakash Naik, M.D., MHS
Johns Hopkins Hospital, Baltimore, MD
Sickle Cell Trait

**Lunch is on us if you visit all our exhibitors!**

DIAMOND SPONSOR

GOLD SPONSOR

SILVER SPONSORS

BRONZE SPONSORS

DIAMOND SPONSOR

CONTACT US
KEEP IN TOUCH
Sign up for our email list, or follow us on social media, to stay in-the-know about the Maryland Sickle Cell Disease Association
Scroll to Top

Breaking News

FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

On December 8, 2023, “The U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signaling an innovative advancement in the field of gene therapy."